BRIEF-Pharming Group and Hyupjin get South Korean marketing authorization for Ruconest

Mon Dec 21, 2015 1:58am EST
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Dec 21 (Reuters) - Pharming Group NV :

* Pharming and Hyupjin announce receipt of the South Korean marketing authorization for Ruconest

* Ruconest is approved for treatment of acute angioedema attacks in adult patients with hereditary angioedema HAE

* Says its South-Korean partner Hyupjin will now seek reimbursement for Ruconest in South Korea Source text for Eikon: Further company coverage: (Gdynia Newsroom:)